The BEAM study, sponsored by Sunnybrook Health Sciences Centre, aims to validate non-invasive ocular measurements as biomarkers for early detection of neurodegenerative diseases, including Alzheimer's Disease and Mild Cognitive Impairment. This study is positioned in a growing market focused on early diagnostics for dementia, which is increasingly critical as the global aging population expands. The findings could enhance the competitive landscape for diagnostic tools in neurodegeneration, potentially leading to partnerships or licensing opportunities with companies specializing in ocular imaging and neurodegenerative diagnostics. The study's collaboration with GE Healthcare indicates a strategic alignment with industry leaders, enhancing its commercial viability.